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Cryptochromes are key components of the circadian clocks that generate and maintain seasonal varia-
tions. The aim of our study was to analyze the associations of CRY1 and CRY2 genetic variants with the
problematicity of seasonal variations, and whether the problematicity of seasonal variations changed
during the follow-up of 11 years. Altogether 21 CRY1 and 16 CRY2 single-nucleotide polymorphisms
(SNPs) were genotyped and analyzed in 5910 individuals from a Finnish nationwide population-based
sample who had filled in the self-report on the seasonal variations in mood and behavior in the year
2000. In the year 2011, 3356 of these individuals filled in the same self-report on the seasonal variations
in mood and behavior. Regression models were used to test whether any of the SNPs associated with the
problematicity of seasonal variations or with a change in the problematicity from 2000 to 2011. In the
longitudinal analysis, CRY2 SNP rs61884508 was protective from worsening of problematicity of seasonal
variations. In the cross-sectional analysis, CRY2 SNP rs72902437 showed evidence of association with
problematicity of seasonal variations, as did SNP rs1554338 (in the MAPK8IP1 and downstream of CRY2).
& 2016 Elsevier Ireland Ltd. All rights reserved.1. Introduction
For the majority of the human population, there are fluctua-
tions in mood and behavior across seasons (Kasper et al., 1989).
Among individuals having mood disorder these seasonal varia-
tions tend to be pronounced (Wehr and Rosenthal, 1989). Seasonal
variations characterize the clinical picture of those with the sea-
sonal pattern or seasonal affective disorder (SAD) (Rosenthal et al.,
1984b). The winter type of SAD is the most common form (Par-
tonen and Lonnqvist, 1998; Patten et al., 2016). Earlier, we have
shown that, of the Finnish general population aged 30 and over,
85% which corresponds to the estimated number of 2,766,037
inhabitants followed a seasonal pattern in mood and behaviors,
38.9% (1,266,531 inhabitants) experienced routine seasonal varia-
tions to the extent of threshold-level SAD, and 2.6% (85,615 in-
habitants) suffered from these symptoms to the extent equal to
SAD (Grimaldi et al., 2009).
Physiological functions and behaviors demonstrate daily and
seasonal variations that are generated and maintained by the cir-
cadian clocks responding to stimuli from the habitat (Meijer et al.,
2007). Within cells on molecular level, cryptochromes guide arved.
.
range of functions of the circadian clocks (Lamia et al., 2011), and
they are necessary for the development of intercellular networks
in the master circadian clock in the cells of the suprachiasmatic
nucleus (Ono et al., 2013) that produces synchronizing signals
throughout the organism (Evans et al., 2015). Environmental light
and ambient temperature of the external 24-hour cycle act to-
gether to dictate the phase and to entrain circadian clocks (Boot-
hroyd et al., 2007), but the change of seasons tends to challenge
their functions (Stoleru et al., 2007). Since most biochemical re-
actions respond robustly to temperature, it might have been used
as the original, universal time-giver to the organism (Buhr et al.,
2010), and the evolution of mechanisms to buffer the effects of
day-to-day (or season-to-season) changes in ambient temperature
expected to favor adaptation (Francois et al., 2012). Concerning
day-active animals, transcription of the cryptochrome genes that
are key components of the circadian clocks is induced in the
evening (Lincoln et al., 2002), and the heat-induced phase shifts of
the circadian clock are severely reduced in the cryptochrome loss-
of-function mutants (Kaushik et al., 2007). Thus, the cryptochrome
proteins regulate the temperature entrainability, and if this were
to hold for mammals as well, including humans, then dysfunction
of cryptochrome proteins may contribute to the seasonal varia-
tions in mood and behavior being experienced as a problem.
Dysfunction of the circadian clocks has been hypothesized to
play a role in the etiology of mood disorders (Bunney and Potkin,
Fig. 1. Schematic of the key functions of cryptochromes in a cell. Cryptochromes (CRY2 and CRY1) are proteins that are repressors in the transcription-translation loops in
the core of circadian clocks, and inhibitors of the cyclic adenosine monophosphate signal pathway. In the cytoplasm, CRY2 and CRY1 inhibit both the alpha-subunit of
stimulatory guanosine-triphosphate-binding proteins coupled to transmembrane receptors and the activity of adenylyl cyclase. Adenylyl cyclase produces the second
messenger cyclic adenosine monophosphate for intracellular signaling. In the nucleus, CRY2 and CRY1 repress the transcription of, e.g., PCK1, G6PC, NR1D1 and PPARA. PCK1 is
a main control point for the regulation of gluconeogenesis, and G6PC encodes a key enzyme in glucose homeostasis. NR1D1 encodes a ligand-sensitive transcription factor
that negatively regulates the expression of core clock proteins, and PPARA encodes a key regulator of lipid metabolism for the peroxisomal beta-oxidation pathway of fatty
acids and for the propagation of clock information to metabolic pathways. By these actions, CRY2 and CRY1 are involved in the functions of circadian clocks and in the
metabolism of glucose and lipids, and they may contribute to mood regulation on daily basis as well as to seasonal variations in mood and behavior. Abbreviations:
AC¼adenylyl cyclase; AMP¼adenosine monophosphate; AMPK¼adenosine-monophosphate-activated protein kinase; ATP¼adenosine triphosphate; cAMP¼cyclic ade-
nosine monophosphate; CRY¼cryptochrome; GPCR¼G protein–coupled receptor; G6PC¼glucose-6-phosphatase, catalytic subunit; Gsα¼stimulatory guanosine-tripho-
sphate-binding protein, alpha subunit; NR1D1¼nuclear receptor subfamily 1, group D, member 1; P¼phosphorus; PCK1¼phosphoenolpyruvate carboxykinase 1 (soluble);
PPARA¼peroxisome proliferator-activated receptor alpha; VIP¼vasointestinal peptide.
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thought to be of key importance, since they are essential to the
normal function of circadian clocks (Ukai-Tadenuma et al., 2011).
Here, the cryptochrome circadian clock 2 (CRY2) and crypto-
chrome circadian clock 1 (CRY1) proteins are the key repressors in
the core of the circadian clock (Dardente et al., 2007; Ozturk et al.,
2007; Ye et al., 2011, 2014). However, CRY2 has a key role in bal-
ancing the expression of cryptochromes, as it not only acts as a
general repressor, but also opposes in specific the actions of CRY1
and inhibits CRY1 from accessing to its targets too early (Anand
et al., 2013). See Fig. 1 for a schematic of the key functions of
cryptochromes in a cell.
CRY2 has been associated with depressive disorders (Lavebratt
et al., 2010; Kovanen et al., 2013), bipolar disorders (Sjoholm et al.,
2010), and greater chronicity of depressive symptoms in patients
with major depressive or bipolar disorder (Fiedorowicz et al.,
2012). On the other hand, CRY1 has earlier been associated with
depression (Soria et al., 2010; Hua et al., 2014) and nominallysignificant association has been observed with lithium treatment
response for bipolar disorder (McCarthy et al., 2011). However, no
association with bipolar disorder has been observed (Shi et al.,
2008; Nievergelt et al., 2005). Thus, data from the very beginning
to date are so far consistent with the hypothesis that CRY2 and
CRY1 proteins modulate circadian and emotional responses, and
therefore CRY2 and CRY1 are highly interesting and relevant target
to study the seasonal variations in mood and behavior in humans.
Here, we hypothesize that there is a variant of CRY2 or CRY1 which
increases the odds for seasonal variations in mood and behavior
being experienced as a problem.
Cryptochromes may be involved not only in regulation of mood
and behavior, but also in that of metabolism of glucose, cholesterol
and triglycerides. In a consortium meta-analysis of genome-wide
association studies using the Homeostasis Model Assessment in-
dices of insulin resistance and beta-cell function, the A-allele of
CRY2 SNP rs11605924 was found to associate with fasting glucose
and beta-cell function, but not to play a major role in type
L. Kovanen et al. / Psychiatry Research 242 (2016) 101–110 1032 diabetes (Dupuis et al., 2010). Later, only a nominal association of
type 2 diabetes was seen with the C-allele of CRY2 SNP rs2292912,
but the finding complemented earlier findings and pointed at the
role for CRY2 in susceptibility to type 2 diabetes (Kelly et al., 2012).
Recently, however, these findings were extended by showing that
CRY2 SNP rs11605924 was associated with glucose levels in heal-
thy children, adolescents and adults, the A-allele being identified
as a glucose-raising allele (Barker et al., 2011). In addition, the
minor alleles of the CRY2 SNPs rs11605924, rs10838524 and
rs7933420 all revealed increases in fasting glucose in a sample of
non-diabetic individuals with the family history of type 2 diabetes
(Machicao et al., 2016). Furthermore, the A-allele of CRY2 SNP
rs11605924 was confirmed to associate with fasting glucose, and
shown to associate with the 2-hour glucose levels after the 75-
gram oral glucose tolerance test if administered during the winter,
but not if administered in the summer (Renstrom et al., 2015). On
the other hand, the minor C-allele of CRY1 SNP rs2287161 was
shown to interact with the level of carbohydrate intake, that is
both a susceptibility factor to type 2 diabetes and a characteristic
of seasonal affective disorder, to modulate fasting insulin and in-
sulin resistance (Dashti et al., 2014). To our knowledge, there are
no earlier data on the associations of CRY1 or CRY2 variants with
cholesterol levels or those of triglycerides. Here, we hypothesizeTable 1
Successfully genotyped CRY1 and CRY2 SNPs, their allele and genotype frequencies, and
Gene SNP BP NCBI36/hg18 A1 A2 M
CRY2 rs7121611 45,864,142 A T 0
rs7121775 45,864,323 C T 0
rs61884508 45,864,932 G T 0
rs75065406 45,864,942 T C 0
rs3747548 45,869,013 A C 0
rs10838524 45,870,177 G A 0
rs2292913 45,877,529 T C 0
rs7945565 45,878,992 G A 0
rs1401419 45,879,739 G A 0
rs72902437 45,882,258 C T 0
rs35488012 45,889,228 G 0
rs117531403 45,891,332 C 0
rs7123390 45,891,418 A G 0
rs4755345 45,891,508 A G 0
rs76545099 45,891,667 T 0
rs17787136 45,894,636 G C 0
rs10838527 45,903,194 G A 0
rs2292910 45,903,613 A C 0
rs3824872 45,905,605 T G 0
rs1554338 45,906,830 G A 0
CRY1 rs4964513 107,375,758 C T 0
rs714359 107,378,845 A G 0
rs12821586 107,380,452 A G 0
rs2287161 107,381,140 C G 0
rs11113153 107,381,770 T C 0
rs8192441 107,385,454 C A 0
rs3741892 107,387,163 C G 0
rs10861688 107,394,048 T C 0
rs10861695 107,415,073 A G 0
rs10861697 107,419,662 C G 0
rs2078074 107,436,806 C T 0
rs59790130 107,440,303 T C 0
rs10437895 107,440,824 C T 0
rs10746077 107,441,552 A G 0
rs11613557 107,442,315 T C 0
rs2888896 107,446,582 T C 0
rs11113179 107,452,785 T C 0
rs10746083 107,454,152 T C 0
rs4964518 107,466,217 T C 0
rs7294758 107,467,829 A T 0
rs17289712 107,468,968 G A 0
rs10778528 107,473,962 G T 0
Abbreviations: BP; Base pair position based on NCBI36/hg18 build. A1; Minor allele. A2;
frequencies (%). HWE; Hardy-Weinberg equilibrium.that there is a variant of CRY2 or CRY1 which increases the odds for
adverse profiles of glucose, cholesterol or triglycerides metabo-
lism, and that such variant is more frequent among those with
problematic seasonal variations in mood and behavior.
Our aim in this prospective study representative of the general
adult population aged 30 years and older was to analyze, whether
there is any CRY1 or CRY2 genetic variant, which associates with a
change in the problematicity of the seasonal variations during the
study period of 11 years, and therefore provides information on
the prognosis. Here, we report CRY2 genetic associations with the
problematicity of seasonal variations in mood and behavior, and in
a longitudinal analysis, with worsening of the problematicity.2. Methods
2.1. Subjects
Our sample included 5910 individuals who had given blood
samples, taken part to the Munich-Composite International Diag-
nostic Interview (M-CIDI) (Wittchen et al., 1998) and filled in the
self-report on the seasonal variations in mood and behavior during
the winter months of the year 2000. Of these 5910 individualsHardy-Weinberg equilibrium p-values.
AF A1A1 A1A2 A2A2 HWE p
.46 1218 (21.0) 2883 (49.6) 1711 (29.4) 0.96
.27 384 (6.6) 2326 (40.0) 3100 (53.4) 0.06
.02 1 (0) 241 (4.1) 5600 (95.9) 0.52
.04 13 (0.2) 421 (7.2) 5414 (92.6) 0.11
.00 0 1 (0) 5847 (100) 1.00
.48 1337 (23.0) 2897 (49.8) 1579 (27.2) 0.92
.05 18 (0.3) 590 (10.1) 5233 (89.6) 0.70
.46 1213 (20.9) 2890 (49.8) 1695 (29.2) 0.79
.46 1211 (20.9) 2909 (50.1) 1681 (29.0) 0.48
.03 2 (0) 313 (5.4) 5499 (94.6) 0.45
.00 0 0 5854 (100) 1.00
.00 0 0 5848 (100) 1.00
.29 431 (7.4) 2445 (42.2) 2915 (50.3) 0.01
.05 18 (0.3) 598 (10.2) 5229 (89.5) 0.80
.00 0 0 5850 (100) 1.00
.28 409 (7.0) 2385 (41.1) 3014 (51.9) 0.03
.12 89 (1.5) 1236 (21.2) 4509 (77.3) 0.67
.34 650 (11.2) 2707 (46.6) 2455 (42.2) 0.02
.25 372 (6.4) 2173 (37.3) 3276 (56.3) 0.65
.05 14 (0.2) 528 (9.1) 5289 (90.7) 0.77
.12 84 (1.4) 1224 (21.1) 4492 (77.4) 0.95
.22 276 (4.8) 2006 (34.6) 3516 (60.6) 0.67
.11 72 (1.2) 1138 (19.5) 4629 (79.3) 0.84
.50 1408 (24.3) 2930 (50.5) 1461 (25.2) 0.43
.17 178 (3.1) 1624 (28.3) 3946 (68.6) 0.49
.01 1 (0) 136 (2.3) 5712 (97.7) 0.56
.49 1395 (24.0) 2937 (50.6) 1477 (25.4) 0.40
.17 164 (2.8) 1642 (28.2) 4011 (69.0) 0.82
.49 1385 (24.0) 2901 (50.4) 1474 (25.6) 0.58
.49 1352 (23.3) 2923 (50.4) 1521 (26.2) 0.48
.42 1017 (17.7) 2815 (48.9) 1930 (33.5) 0.87
.06 26 (0.4) 692 (11.8) 5131 (87.7) 0.58
.49 1398 (24.0) 2936 (50.5) 1482 (25.5) 0.46
.42 1027 (17.6) 2832 (48.7) 1960 (33.7) 0.96
.06 26 (0.4) 692 (11.8) 5130 (87.7) 0.58
.42 1019 (17.6) 2830 (48.8) 1947 (33.6) 0.87
.08 39 (0.7) 833 (14.3) 4942 (85.0) 0.53
.49 1391 (23.9) 2941 (50.6) 1481 (25.5) 0.37
.07 30 (0.5) 778 (13.3) 5027 (86.2) 1.00
.01 0 97 (1.7) 5758 (98.3) 1.00
.05 6 (0.1) 524 (9.0) 5308 (90.9) 0.07
.48 1358 (23.3) 2926 (50.3) 1533 (26.4) 0.62
Major allele. MAF; Minor allele frequency. A1A1, A1A2, A2A2; genotype counts and
Table 2
General characteristics of the participants (n¼5739) in the year 2000.
Characteristic n %
Gender
Female 3195 56
Male 2544 44
Seasonal variation in sleep duration
Cases 4178 73.88
Controls 1477 26.12
Seasonal variation in social activity
Cases 3980 71.72
Controls 1569 28.28
Seasonal variation in mood
Cases 4263 76.03
Controls 1344 23.97
Seasonal variation in weight
Cases 2771 49.47
Controls 2830 50.53
Seasonal variation in appetite
Cases 2404 42.68
Controls 3228 57.32
Seasonal variation in energy level
Cases 4235 75.34
Controls 1386 24.66
Seasonal variation as a problem
No variation 361 7.06
Non-problematic variation 3824 74.75
Problematic variation 931 18.20
n mean s.d.
Age, years 5739 53.13 15.04
BMI, kg/m2 5722 26.97 4.70
GSS, score points 5469 5.04 3.07
Abbreviations: BMI; body mass index. GSS; global seasonality score.
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and behavior again during the winter months of the year 2011. The
sample is part of the national Health 2000 survey (Aromaa and
Koskinen, 2004) of Finnish population aged 30 years and older
(n¼8028) and its follow-up survey in the year 2011. The study was
approved by the ethics committees of the National Public Health
Institute and the Helsinki and Uusimaa Hospital District. The study
was carried out in accordance with the principles of the Declara-
tion of Helsinki and its amendments. All participants provided a
written informed consent.
2.2. Phenotypes
The participants filled in a questionnaire of lifetime seasonal
variations in mood and behavior adapted from the Seasonal Pat-
tern Assessment Questionnaire (SPAQ) (Rosenthal et al., 1984a).
The six items of sleep duration, social activity, mood, weight, ap-
petite, and energy level had been scored from 0 to 3 (none, slight,
moderate, or marked variation) rather than from 0 to 4 (none,
slight, moderate, marked, or extremely marked variation). The
psychometric properties of this modified questionnaire have been
reported to be good (Rintamaki et al., 2008). The participants were
also asked to what degree seasonal variations if any were a pro-
blem (no variations, no problem, and mild, moderate, marked, or
severe problem).
For the purpose of the cross-sectional analysis, a variable was
formed as follows: no seasonal variations (all six items no varia-
tion and problem degree no variations), non-problematic seasonal
variations (at least 1 item with variation and variation is no pro-
blem), or problematic seasonal variations (at least 1 item with
variation and variation is a problem). For the purpose of the
longitudinal analysis, the individual change in the aforementioned
variable was computed: equal (n¼1625), worse (n¼928), or better
(n¼428). Supplementary material 1 shows the computation of the
variables for the cross-sectional (Supplementary Table 1) and
longitudinal analysis (Supplementary Table 2).
2.3. Health examination
Height and weight were measured, and the body-mass index
(BMI) was calculated. Body circumference measurements were
taken using a regular, flexible tailor's measuring tape at waist and
hip level in line with recommendations for anthropometric mea-
surements in population studies.
Current instructions of the Finnish Hypertension Society
working group were followed for blood pressure measurements
that were taken after calibration using a standard mercury man-
ometer (Mercuro 300; Speidel & Keller, Jungingen, Germany). The
measurement was repeated two minutes after the first one, and
the average of the two was used for analysis.
2.4. Laboratory analyses
As part of the health examination, venous blood samples were
drawn and laboratory measures included in the analysis were total
cholesterol (CHOD PAP, Olympus System Reagent, Freiburg, Ger-
many), high-density lipoprotein (HDL) cholesterol (HDL-C Plus,
Roche Diagnostics, Penzberg, Germany), triglycerides (GPO PAP,
Olympus System Reagent, Freiburg, Germany), and plasma glucose
(Hexokinase, Olympus System Reagent, Freiburg, Germany). LDL
cholesterol was calculated with the Friedewald formula (Friede-
wald et al., 1972). All these samples were determined en-
zymatically with a clinical chemistry analyzer (Olympus AU400,
Hamburg, Germany) at the Social Insurance Institution (Kela),
Research and Development Unit, Finland. Plasma insulin con-
centrations were determined using a radioimmunoassay(Phadeseph Insulin RIA, Pharmacia, Uppsala, Sweden). Home-
ostasis Model Assessment indices of insulin resistance (HOMA-IR)
and beta-cell function (HOMA-B) were calculated according to the
following formula: HOMA-IR¼fasting glucose (mmol/L) fasting
insulin (mU/L) divided by 22.5 and HOMA-B¼20 [(fasting in-
sulin) divided by (fasting glucose minus 3.5)] (Matthews et al.,
1985). Serum 25-hydroxyvitamin D3 concentrations were de-
termined using a radioimmunoassay (DiaSorin, Saluggia, Italy).
The laboratory took part in the External Quality Assessment
schemes (Labquality, Helsinki, Finland), the accuracy for the lipid
determinations was also calculated by the Lipids and lipoproteins
program, and the quality of the results of the series of all the
analyses was ascertained.
2.5. Gene and SNP selection
CRY1 and CRY2 single-nucleotide polymorphism (SNP) selectionwas
based on HapMap phase 3 data (http://www.hapmap.org/) and tagging
was done using the Tagger program in the Haploview 4.1 software
(Barrett et al., 2005). The linkage disequilibrium (LD), within the gene
and 10 kb of their 5′ and 3′ flanking regions, i.e., 122 kb for CRY1
(chr12:105 899–106 021 kb, NCBI36/hg18 assembly), and 56 kb for
CRY2 (chr11:45,815–45,871 kb), was used to select tag SNPs capturing
most of the genetic variation. The aim was to capture all the SNPs
having a minor allele frequency (MAF) of 45% in the European po-
pulation (CEU and TSI) in the HapMap database. The pair-wise r2 was
set to Z0.9 in order to select a tag SNP among the SNPs that were in
LD. Ten out of 21 CRY1 and ten out of 34 CRY2 SNPs fulfilled the cri-
terion and were all successfully included in the genotyping multiplex.
In addition to the aforementioned tag-SNPs, 22 potentially functional
variants in CRY1 (12 variants) and CRY2 (10 variants) were included in
Table 3
Baseline characteristics of the participants with problematic, non-problematic and no variation.
problematic variation non-problematic variation no variation problematic vs. non-
problematic
problematic vs. no variation
n mean %/SD n mean %/SD n mean %/SD χ2/ t p χ2/t p
Male gender 365 39.21 1675 43.80 201 55.68 6.27 0.01 28.01 0.0000001
Female gender 566 60.79 2149 56.20 160 44.32
Age 931 53.55 15.07 3824 51.43 14.27 361 55.42 16.46 3.89 0.0001 1.87 0.06
Glucose 931 5.58 1.38 3822 5.52 1.13 361 5.66 1.36 1.27 0.20 0.95 0.34
Total cholesterol 931 5.93 1.16 3822 5.91 1.09 361 6.00 1.13 0.54 0.59 0.96 0.34
HDL cholesterol 931 1.33 0.38 3822 1.34 0.38 361 1.29 0.37 1.11 0.27 1.69 0.09
LDL cholesterol 928 3.66 1.11 3805 3.70 1.03 360 3.80 1.10 0.87 0.39 1.96 0.05
Triglycerides 931 1.69 1.23 3822 1.56 0.98 361 1.66 1.07 2.92 0.004 0.37 0.71
25-hydroxyvitamin D3 880 44.92 16.55 3672 45.57 16.85 342 43.58 16.97 1.03 0.30 1.25 0.21
Insulin 905 9.11 9.06 3762 9.71 14.37 348 9.41 7.63 1.59 0.11 0.61 0.54
Weight 930 77.00 16.20 3819 76.15 15.33 360 75.97 15.22 1.44 0.15 1.07 0.29
Waist circumference 922 93.90 14.11 3792 92.03 13.06 354 93.21 13.51 3.67 0.0003 0.81 0.42
BMI 930 27.45 5.01 3818 26.77 4.61 360 26.63 4.49 3.74 0.0002 2.85 0.004
GSS 874 8.00 2.87 3734 5.07 2.47 361 0.00 0.00 27.82 o2.2e-16 82.42 o2.2e-16
Systolic blood pressure 925 133.51 21.52 3816 134.11 21.02 361 136.06 20.36 0.76 0.45 1.98 0.05
Diastolic blood
pressure
923 81.33 11.48 3814 81.70 11.24 361 81.81 10.63 0.88 0.38 0.71 0.48
HOMA-IR 905 2.68 4.32 3760 2.46 6.31 348 2.58 3.17 1.26 0.21 0.44 0.66
HOMA-B 903 95.47 69.71 3755 94.37 159.25 347 87.12 53.28 0.32 0.75 2.27 0.02
GHQ 908 3.89 3.95 3787 1.49 2.48 355 0.86 2.04 17.50 o2.2e-16 17.82 o2.2e-16
MBI 485 1.82 1.11 2421 1.06 0.81 175 0.80 0.78 14.33 o2.2e-16 13.10 o2.2e-16
Hours of sleep 891 7.47 1.36 3685 7.46 1.05 343 7.50 1.33 0.21 0.84 0.34 0.73
Hip circumference 921 102.86 10.29 3792 101.40 9.30 354 100.89 9.46 3.93 0.0001 3.25 0.001
HDL, high-density lipoprotein.
LDL, low-density lipoprotein.
BMI, body-mass index.
GSS, global seasonality score.
HOMA-IR, insulin resistance index.
HOMA-B, beta-cell function index.
L. Kovanen et al. / Psychiatry Research 242 (2016) 101–110 105the genotyping multiplexes. These additional SNPs were selected using
Pupasuite (Conde et al., 2006), Variowatch (Cheng et al., 2012) and
dbSMR (Hariharan et al., 2009) databases. See Table 1 for the altogether
42 selected SNPs.
2.6. Genotyping
Genomic DNA was isolated from whole blood according to
standard procedures. The SNPs were genotyped at the Institute for
Molecular Medicine Finland, Technology Centre, University of
Helsinki using the MassARRAY iPLEX method (Sequenom, San
Diego, CA, USA) (Jurinke et al., 2002), with excellent success
(495%) and accuracy (100%) rates (Lahermo et al., 2006). For
quality control purposes, positive (CEPH) and negative water
controls were included in each 384-plate. Genotyping was per-
formed blind to phenotypic information.
171 of 5910 individuals were excluded due to a high missing
genotype rate (i.e. 40.1). The total genotyping rate in the re-
maining individuals was 0.999. Three CRY2 SNPs turned out to be
non-polymorphic (rs35488012, rs117531403, rs76545099). Two
SNPs were excluded from the analyses because their minor allele
frequency was less than 0.01 (CRY2 rs3747548, CRY1 rs7294758).
Finally, there were 5739 individuals and 37 SNPs for the statistical
analyses.
2.7. Statistical analyses
Statistical analyses were performed using logistic regression
and additive genetic model controlling for age and sex with PLINK
software v1.07 (Purcell et al., 2007). Subjects having problematic
seasonal variations were compared to subjects with non-proble-
matic seasonal variations, and to subjects with no seasonal var-
iation. A change in the seasonal variations for the better, and achange for the worse were compared to no change. Haplotype
blocks were defined using Haploview software (Barrett et al.,
2005) and the confidence interval algorithm. Only haplotypes with
more than 5% frequency are reported. In order to corrected for the
multiple SNPs within a gene, the gene-based analysis was con-
ducted using the set-based test in PLINK software with the default
settings and 10,000 permutations, yielding the empirical p-values.3. Results
In Table 1, the genotypes, allele frequencies and the Hardy-
Weinberg equilibrium p-values are shown for all the 42 SNPs that
were successfully genotyped in this study. The general character-
istics of all the participants are presented in Table 2 and for the
three groups in Table 3. The group with problematic variation had
the highest BMI and hip circumference. The group with non-pro-
blematic variation had lowest triglycerides and waist cir-
cumference. The group with no variation had highest LDL cho-
lesterol and systolic blood pressure and lowest HOMA-IR. The
Haploview analysis yielded three haplotype blocks for CRY1 and
one haplotype block for CRY2 gene (Figs. 2 and 3) which had 11
and five common (45% frequency) haplotypes, respectively.
3.1. Cross-sectional analysis
CRY1 SNP rs714359 (A allele, OR¼1.33, 95% CI 1.07–1.66,
p¼0.01; see Table 4) showed nominally significant association
with the problematicity of seasonal variations (problematic vs. no
variation), and rs714359 (A allele, OR¼1.14, 95% CI 1.01–1.29,
p¼0.03) and rs2287161 (C allele, OR¼0.90, 95% CI 0.81–1.00,
p¼0.05) with the problematicity of seasonal variations (proble-
matic vs. non-problematic). The set-based analysis did not support
Fig. 2. The analyzed CRY1 SNPs, their location and the haplotype block structure constructed using the Haploview program showing r2 values.
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including rs714359 showed nominally significant association with
the problematicity of seasonal variations (problematic vs. no var-
iation, OR¼1.33, p¼0.01; and problematic vs. non-problematic,
OR¼1.14, p¼0.03; see Table 6). All the SNP and haplotype asso-
ciation analysis results are shown in Supplementary material 2
(Supplementary Table 3 for SNP association results and Supple-
mentary Table 4 for haplotype association results).
CRY2 SNPs rs1554338 (G allele, OR¼0.67, 95% CI 0.51–0.87,
p¼0.0035) and rs72902437 (C allele, OR¼1.45, 95% CI 1.08–1.93,
p¼0.01; see Table 4) showed nominally significant association
with the problematicity of seasonal variations (problematic var-
iation vs. non-problematic variation). The set-based analysis sup-
ported the association of the two SNPs with the problematicity
(empirical set-based p¼0.03; see Table 5). The CRY2 haplotype
TTTCACAATGGCACT (OR¼0.77, p¼0.03; see Table 6) was also as-
sociated with the problematicity of seasonal variations (proble-
matic variation vs. non-problematic variation).
3.2. Longitudinal analysis
CRY2 SNP rs61884508 (G allele, OR¼0.52, 95% CI 0.33–0.82,
p¼0.004, q¼0.14; see Table 3) was associated with worsening of
the problematicity of seasonal variations during the follow-up. The
set-based analysis supported the SNP association (empirical set-
based p¼0.02; see Table 5).3.3. Additional analysis
For the aforementioned five SNPs, the results from their asso-
ciations with the laboratory measurements are given in Supple-
mentary material 3. Among those with problematic seasonal var-
iations, the AA-genotypes of CRY1 SNP rs714359 had lower HDL
cholesterol levels, higher insulin levels, and greater HOMA-IR and
HOMA-B indices than GG-genotypes, the GA genotypes being in-
termediate. Concerning the CRY1 SNP rs2287161, among those
with no seasonal variation the CG-genotypes had lower HDL
cholesterol levels than CC-genotypes, and among those with non-
problematic seasonal variations the GG-genotypes had lower HDL
cholesterol levels than CG-genotypes.
The TT-genotypes, as compared with the CT-genotypes, of CRY2
SNP rs72902437 had greater HOMA-B indices among those with
non-problematic seasonal variations, and higher systolic and dia-
stolic blood pressures among those with no seasonal variation.
Concerning the CRY2 SNP rs1554338, the GG-genotypes had
higher total and LDL cholesterol levels and lower HDL cholesterol
levels than the AA-genotypes among those with non-problematic
seasonal variations.
Among those with worsening of the problematicity of seasonal
variations, the TT-genotype carriers, as compared with the GT-
genotype carriers, of CRY2 SNP rs61884508 had higher levels of
triglycerides at the baseline.
Fig. 3. The analyzed CRY2 SNPs, their location and the haplotype block structure constructed using the Haploview program showing r2 values.
Table 4
Longitudinal and cross-sectional nominally significant (po0.05) CRY1 and CRY2
SNP association results.
Gene Phenotype SNP A1 n OR L95 U95 p
CRY1 Problematic vs. no
variation
rs714359 A 1289 1.33 1.07 1.66 0.01
Problematic vs.
non-problematic
rs714359 A 4746 1.14 1.01 1.29 0.03
Problematic vs.
non-problematic
rs2287161 C 4732 0.90 0.81 1.00 0.05
CRY2 Problematic vs.
non-problematic
rs1554338 G 4752 0.67 0.51 0.87 0.003
Problematic vs.
non-problematic
rs72902437 C 4746 1.45 1.08 1.93 0.01
Worse rs61884508 G 2552 0.52 0.33 0.82 0.004
Abbreviations: A1; Tested allele (minor allele). N; Number of genotypes for the
phenotype. OR; Odds ratio. L95, U95; Lower and upper bounds of 95% confidence
interval for odds ratio.
Table 5
Results of the set-based analysis.
SET Phenotype NSNP NSIG NSIGLD EMP SNPs
CRY1 Problematic vs. no
variation
21 1 1 0.07 rs714359
Problematic vs. non-
problematic
21 2 2 0.31 rs714359|
rs2287161
Better 21 0 0 1.00 –
Worse 21 0 0 1.00 –
CRY2 Problematic vs. no
variation
16 0 0 1.00 –
Problematic vs. non-
problematic
16 2 2 0.03 rs1554338|
rs72902437
Better 16 0 0 1.00 –
Worse 16 1 1 0.02 rs61884508
Abbreviations: NSNP; Number of SNPs in the set. NSIG; Number of SNPs with
po0.05. NSIGLD; Number of significant SNPs also passing LD-criterion (r240.5).
EMP; Empirical set-based p-value. SNPs; List of SNPs in the set.
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In the longitudinal analysis, we found evidence that carriers of
the CRY2 SNP rs61884508 G-allele had the decreased odds for the
worsening of the seasonal variations in mood and behavior as a
problem during the 11-year follow-up. In addition, in among the
participants that had worsening of the seasonal variations, thetriglycerides levels were associated with the CRY2 SNP
rs61884508, the carriers of GT-genotype having lower levels of
triglycerides than the carriers of TT-genotype. The CRY2 SNP
rs61884508 is located upstream of CRY2 gene and was selected to
be genotyped because it is located within a putative transcription
factor binding site, and it could thus have a role in transcriptional
regulation.
In the cross-sectional analysis, we found that the SNP
Table 6
Longitudinal and cross-sectional nominally significant CRY1 and CRY2 haplotype association results.
Gene Phenotype SNP1 SNP2 Haplotype F OR p
CRY1 Problematic vs. no variation rs4964513 rs12821586 TAG 0.22 1.33 0.01
Problematic vs. non-problematic rs4964513 rs12821586 TAG 0.22 1.14 0.03
CRY2 Problematic vs. non-problematic rs7121611 rs3824872 TTTCACAATGGCACT 0.06 0.77 0.03
Abbreviations: SNP1; SNP ID of the first SNP (5′). SNP2; SNP ID of the last SNP (3′). OR; Odds ratio. F; frequency of the haplotype.
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predisposed to more severe seasonal variations, i.e., those being
problematic vs. non-problematic to the individual. Earlier, the SNP
rs1554338 G-allele has been associated with having the seasonal
pattern in bipolar disorder (Geoffroy et al., 2015) and nominally
(p¼0.031, not holding after multiple correction) with bipolar I
disorder. Here, we found that the GG-genotype associated with
both higher total and higher LDL cholesterol levels but lower HDL
cholesterol levels compared to AA-genotype, indicating an un-
favorable circulating lipids profile, and that it was seen only
among those with non-problematic seasonal variations. Intrigu-
ingly, the SNP rs1554338 is located in the upstream of MAPK8IP1
(downstream of CRY2). The MAPK8IP1 gene is indicated in the
pancreatic beta-cell function (Waeber et al., 2000), and its scaf-
folding protein MAPK8IP1 (mitogen-activated protein kinase 8 in-
teracting protein 1) is a key regulator of autophagosome transport
in neurons (Fu and Holzbaur, 2014) and has a role in protection of
dopaminergic neurons and levels of catecholamines in the stria-
tum (Xia et al., 2001).
We also found that if there were seasonal variations in mood
and behavior but they were not a problem, the CRY2 SNP
rs72902437 CT-genotype was associated with a lower HOMA-B
index, or a worse beta-cell function compared to TT-genotype,
indicating an increased diabetes risk. In contrast, among those
with no seasonal variation, systolic and diastolic blood pressures
were lower in the carriers of the CRY2 SNP rs72902437 CT-geno-
type compared to TT-genotype, indicating a decreased hyperten-
sion risk.
The A-allele of CRY2 SNP rs10838524 that was earlier associated
with greater chronicity of depressive symptoms in patients with
major depressive or bipolar disorder (Fiedorowicz et al., 2012) did
not associate with seasonality in our study. However, the A-allele
of the CRY2 SNP rs10838524 was part of TTTCACAATGGCACT
haplotype that protected from seasonal variations being proble-
matic in our cross-sectional analysis.
The CRY1 SNP rs714359 was indicated to influence not only
HDL cholesterol levels, but also insulin levels and beyond, as it was
involved in insulin resistance and beta-cell function as well. In-
triguingly, this influence was seen only among those with pro-
blematic seasonal variations. These findings are well in agreement
with the earlier report of the influence of the CRY1 SNP rs2287161
had on fasting insulin and insulin resistance (Dashti et al., 2014).
Our study has some strengths and limitations. Our dataset was
rather big and derived from a nationwide representative sample of
the general adult population aged 30 years and over. In addition,
the cryptochrome genes were well covered. We report here, for
the first time, longitudinal data on the influence of CRY2 genetic
variants on the seasonal variations in mood and behavior experi-
enced as a problem. Since problematic seasonal symptoms of
mood and behavior are common on population level, our findings
might help early identification of individuals who will have wor-
sening of these symptoms.
On the other hand, weaknesses of our study are that the as-
sessment of seasonal variations in mood and behavior was based
on the self-report only, and that some participants were lost in the
follow-up. In addition, the associated SNPs and haplotype wererather rare. Therefore, replication in another independent sample
is needed to confirm our findings, since the minor allele frequency
is known to affect the likelihood of a false positive result.
In conclusion, this association analysis has demonstrated an
effect of CRY2 genetic variants in the problematic seasonal varia-
tions, and more importantly, with worsening of these seasonal
variations as a problem in a longitudinal analysis.Appendix A. Supplementary material
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.psychres.2016.05.
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